Economic Burden of Chemotherapy in Non-Hodgkin Lymphoma Patients under Indonesia’s National Health Insurance (JKN): A Cost of Illness Analysis in Samarinda

Erfan Abdissalam; Syarah Yulistia; Bilqis Nurganiyu; Fitri Ayu Wahyuni; Septiayu Dwi Hartienah

doi:10.30872/jtpc.v10i2.406

Authors

Erfan Abdissalam Faculty of Pharmacy, Universitas Mulawarman Author https://orcid.org/0000-0001-5987-1212
Syarah Yulistia Faculty of Pharmacy, Universitas Muhammadiyah Kalimantan Timur Author
Bilqis Nurganiyu Faculty of Pharmacy, Universitas Mulawarman Author
Fitri Ayu Wahyuni Faculty of Pharmacy, Universitas Mulawarman Author https://orcid.org/0000-0002-1530-6307
Septiayu Dwi Hartienah Faculty of Pharmacy, Universitas Mulawarman Author https://orcid.org/0000-0002-6165-6877

DOI:

https://doi.org/10.30872/jtpc.v10i2.406

Keywords:

INA-CBG, health financing, pharmacoeconomics, societal perspective, healthcare costs

Abstract

Non-Hodgkin lymphoma is a type of cancer affecting the lymphatic system, characterized by a high prevalence both globally and nationally. Chemotherapy is the primary treatment for this condition; however, it often imposes a substantial financial burden on patients. This study assessed chemotherapy-related costs incurred by patients diagnosed with non-Hodgkin lymphoma at a general hospital within the JKN Program for INA-CBG Regional 4 Tariff. Utilizing a descriptive observational design with a cross-sectional approach, the research was conducted retrospectively on 81 chemotherapy sessions that occurred in the second half of fiscal year 2024. Data were collected from medical records, payment receipts, and patient interviews. The findings revealed that total chemotherapy expenses reached Rp489,883,759, with an average cost of Rp6,154,302 per chemotherapy visit. The largest share of these costs was attributable to direct medical expenses, particularly cytostatic drugs, totaling Rp305,511,322. Additionally, direct non-medical costs totaled Rp 56,206,760, and indirect costs amounted to Rp 7,451,631. The drug incurring the highest cost burden was Rituximab 500 mg, with an average price of Rp8,250,750 per vial. Chemotherapy for patients with non-Hodgkin lymphoma imposes a significant economic burden, particularly for pharmaceuticals.

Downloads

Download data is not yet available.

Author Biographies

Erfan Abdissalam, Faculty of Pharmacy, Universitas Mulawarman

Department of Clinical and Community Pharmacy
Bilqis Nurganiyu, Faculty of Pharmacy, Universitas Mulawarman

Department of Pharmacognosy and Medicinal Chemistry
Fitri Ayu Wahyuni, Faculty of Pharmacy, Universitas Mulawarman

Department of Clinical and Community Pharmacy
Septiayu Dwi Hartienah, Faculty of Pharmacy, Universitas Mulawarman

Department of Clinical and Community Pharmacy

References

[1] R. M. Nirmal, “Diagnosis of malignant lymphoma – An overview,” Journal of Oral and Maxillofacial Pathology, vol. 24, no. 2, pp. 195–199, May 2020, doi: 10.4103/0973-029X.294653.

[2] R. Singh et al., “Non-Hodgkin’s lymphoma: A review,” J. Family Med. Prim. Care, vol. 9, no. 4, p. 1834, 2020, doi: 10.4103/jfmpc.jfmpc_1037_19.

[3] M. Sánchez-Beato et al., “A genetic profiling guideline to support diagnosis and clinical management of lymphomas,” Clinical and Translational Oncology, vol. 26, no. 5, pp. 1043–1062, Sep. 2023, doi: 10.1007/s12094-023-03307-1.

[4] S. M. Horwitz et al., “NCCN Guidelines Insights: Non-Hodgkin’s Lymphomas, Version 3.2016,” Journal of the National Comprehensive Cancer Network, vol. 14, no. 9, pp. 1067–1079, Sep. 2016, doi: 10.6004/jnccn.2016.0117.

[5] H. Weng, H. Hu, Y. Zhao, Y. Xu, P. Chen, and P. Huang, “Clinical diagnostic model for predicting indolent or aggressive lymphoma based on clinical information and ultrasound features of superficial lymph nodes,” Eur. J. Radiol., vol. 181, p. 111738, Dec. 2024, doi: 10.1016/j.ejrad.2024.111738.

[6] F. Bray et al., “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 74, no. 3, pp. 229–263, May 2024, doi: 10.3322/caac.21834.

[7] M. Elmadani, S. Klara, M. Mustafa, E. K. Kiptulon, and M. Orsolya, “Global Burden of Rare Cancers: Insights from GLOBOCAN 2022 Estimates,” Cancers (Basel)., vol. 17, no. 10, p. 1721, May 2025, doi: 10.3390/cancers17101721.

[8] World Health Organization, “Cancer Today GLOBOCAN 2022: Indonesia Population Factsheets,” Lyon, Feb. 2024.

[9] B. S. Imber and J. Yahalom, “Radiotherapy for Non-Hodgkin Lymphomas,” The Cancer Journal, vol. 26, no. 3, pp. 217–230, May 2020, doi: 10.1097/PPO.0000000000000453.

[10] B. Hough, O. Lytvynova, A. Sindel, P. Willard, and V. Yazbeck, “New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma,” Expert Opin. Pharmacother., vol. 25, no. 12, pp. 1677–1689, Aug. 2024, doi: 10.1080/14656566.2024.2393759.

[11] T. Hofmarcher, A. Manzano García, N. Wilking, and P. Lindgren, “The Disease Burden and Economic Burden of Cancer in 9 Countries in the Middle East and Africa,” Value Health Reg. Issues, vol. 37, pp. 81–87, Sep. 2023, doi: 10.1016/j.vhri.2023.05.005.

[12] E. Abdissalam, R. N. Azmi, B. D. Putra, A. P. Anggraeni, A. Rahman, and M. F. H. Firdaus, “Comparing the Financial Burden of Colorectal Cancer Chemotherapy on Indonesian Healthcare Insurance (JKN) Coverage: A Study in East Kalimantan,” Journal of Tropical Pharmacy and Chemistry (J. Trop. Pharm. Chem), vol. 9, no. 2, pp. 245–255, 2025.

[13] K. F. Hamidah, M. Rahmadi, E. Abdissalam, I. Septiani, F. N. Utomo, and W. R. Batubara, “Medication complexity and COVID-19 pandemic impact on the cost burden in non-COVID elderly patients at the emergency department,” Pharmacy Education, vol. 23, no. 4, pp. 264–268, Oct. 2023, doi: 10.46542/pe.2023.234.264268.

[14] Y. Yulistiani, E. Abdissalam, A. Rahem, N. F. Hamidi, and F. N. Utomo, “Cost burden of chemotherapy for Indonesian healthcare insurance and social security/Jaminan Kesehatan Nasional (JKN) patients with non-Hodgkin lymphoma,” Journal of Oncology Pharmacy Practice, Jun. 2024, doi: 10.1177/10781552241261250.

[15] R. Kanesvaran, E. Y. T. Wong, B. Keam, N. Prasongsook, H. Malhotra, and J.-Y. Blay, “Quality-of-care indicators for oncology management: an analysis of Asia-Pacific healthcare and oncology indicators,” ESMO Open, vol. 10, no. 3, p. 104293, Mar. 2025, doi: 10.1016/j.esmoop.2025.104293.

[16] Ministry of Health of the Republic of Indonesia, “Minister of Health Regulation Number 76 of 2016 concerning Guidelines for Indonesian Case Base Groups (INA-CBG) in the Implementation of National Health Insurance,” 2016, Ministry of Law and Human Rights of the Republic of Indonesia, Jakarta, Indonesia.

[17] A. Sabermahani, M. J. Sirizi, F. Zolala, and S. Nazari, “Out-of-Pocket Costs and Importance of Nonmedical and Indirect Costs of Inpatients,” Value Health Reg. Issues, vol. 24, pp. 141–147, May 2021, doi: 10.1016/j.vhri.2020.05.004.

[18] N. Iragorri, C. de Oliveira, N. Fitzgerald, and B. Essue, “The Out-of-Pocket Cost Burden of Cancer Care—A Systematic Literature Review,” Current Oncology, vol. 28, no. 2, pp. 1216–1248, Mar. 2021, doi: 10.3390/curroncol28020117.

[19] J. R. Beard et al., “The World report on ageing and health: a policy framework for healthy ageing,” The Lancet, vol. 387, no. 10033, pp. 2145–2154, May 2016, doi: 10.1016/S0140-6736(15)00516-4.

[20] U. Anand et al., “Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics,” Genes Dis., vol. 10, no. 4, pp. 1367–1401, Jul. 2023, doi: 10.1016/j.gendis.2022.02.007.

[21] N. Shimizu et al., “Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma,” Journal of Chemotherapy, vol. 34, no. 4, pp. 258–263, May 2022, doi: 10.1080/1120009X.2021.1988202.

[22] M.-C. Cai et al., “Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial,” Lancet Reg. Health West. Pac., vol. 50, p. 101160, Sep. 2024, doi: 10.1016/j.lanwpc.2024.101160.

[23] P. Martinez and J.-M. Sabatier, “Rethinking corticosteroids use in oncology,” Front. Pharmacol., vol. 16, Mar. 2025, doi: 10.3389/fphar.2025.1551111.

[24] E. P. Ludirdja, N. M. R. A. Rena, K. Suega, and M. Bakta, “Satu tahun kesintasan penderita limfoma non-hodgkin berdasarkan klasifikasi histopatologi working formulation,” Jurnal Penyakit Dalam Udayana, vol. 2, no. 2, pp. 28–31, Dec. 2018, doi: 10.36216/jpd.v2i2.32.

[25] T. A. Pangestu, H. Sulistyo, W. Djatmiko, D. Novrial, and H. R. Mardhihusodo, “Korelasi Usia dan Jenis Kelamin dengan Grading Limfoma Non Hodgkin Sel B di RSUD Prof. Dr. Margono Soekarjo Purwokerto,” Mandala of Health, vol. 17, no. 1, p. 51, May 2024, doi: 10.20884/1.mandala.2024.17.1.9564.

[26] T. A. Pangestu, H. Sulistyo, W. Djatmiko, D. Novrial, and H. R. Mardhihusodo, “Korelasi Usia dan Jenis Kelamin dengan Grading Limfoma Non-Hodgkin Sel B di RSUD Prof. Dr. Margono Soekarjo Purwokerto,” Mandala Of Health, vol. 17, no. 1, p. 51, May 2024, doi: 10.20884/1.mandala.2024.17.1.9564.

[27] W. Liu et al., “Burden of lymphoma in China, 2006–2016: an analysis of the Global Burden of Disease Study 2016,” J. Hematol. Oncol., vol. 12, no. 1, p. 115, Dec. 2019, doi: 10.1186/s13045-019-0785-7.

[28] Y. Susanti, S. Syofyan, K. Khairani, and B. Hermanto, “Hak Pasien dalam Menentukan Layanan Kesehatan dalam Hubungannya dengan Kelas Rawat Inap Standar BPJS Kesehatan,” UNES Law Review, vol. 6, no. 4, pp. 12184–12193, 2024.

[29] P. Pramana and C. W. Priastuty, “Perspektif Masyarakat Pengguna BPJS Kesehatan mengenai Kebijakan Kelas Rawat Inap Standar (KRIS),” Jurnal Jaminan Kesehatan Nasional, vol. 3, no. 1, Jun. 2023, doi: 10.53756/jjkn.v3i1.98.

[30] J. K. N. Palupi, V. Wardhani, and S. Andarini, “Determinan Pilihan Naik Kelas Perawatan Rumah Sakit dari Kelas I ke Kelas VIP,” Jurnal Kebijakan Kesehatan Indonesia, vol. 5, no. 4, pp. 176–183, 2016.

[31] S. L. Tsuroyya and C. Maharani, “Systematic Literature Review: Faktor yang Berhubungan dengan Kepatuhan Peserta PBPU dalam Membayar Iuran JKN,” Jurnal Kebijakan Kesehatan Indonesia, vol. 12, no. 4, p. 193, Dec. 2023, doi: 10.22146/jkki.87944.

[32] M. Das, “Indonesia launches three programmes to boost cancer care,” Lancet Oncol., vol. 24, no. 2, p. 131, Feb. 2023, doi: 10.1016/S1470-2045(23)00010-4.

[33] R. S. Salma, M. P. Sedana, and S. U. Yudho, “CHOP and R-CHOP Therapeutic Responses in Non-Hodgkin Lymphoma Patients in Dr. Soetomo General Hospital Surabaya,” Biomolecular and Health Science Journal, vol. 1, no. 2, p. 93, Nov. 2018, doi: 10.20473/bhsj.v1i2.9244.

[34] W. L. Susanti, A. Nurrochmad, and R. Murwanti, “Perbandingan Kemoterapi CHOP dan RCHOP terhadap Kejadian Anemia pada Pasien Kanker Limfoma Non-Hodgkin,” Majalah Farmaseutik, vol. 19, no. 2, pp. 289–296, 2023.

[35] E. Dabbish et al., “Insights on cyclophosphamide metabolism and anticancer mechanism of action: A computational study,” J. Comput. Chem., vol. 45, no. 10, pp. 663–670, Apr. 2024, doi: 10.1002/jcc.27280.

[36] M. Kciuk et al., “Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity,” Cells, vol. 12, no. 4, p. 659, Feb. 2023, doi: 10.3390/cells12040659.

[37] J. Škubník, V. S. Pavlíčková, T. Ruml, and S. Rimpelová, “Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics,” Biology (Basel)., vol. 10, no. 9, p. 849, Aug. 2021, doi: 10.3390/biology10090849.

[38] R. S. Goodman, D. B. Johnson, and J. M. Balko, “Corticosteroids and Cancer Immunotherapy,” Clinical Cancer Research, vol. 29, no. 14, pp. 2580–2587, Jul. 2023, doi: 10.1158/1078-0432.CCR-22-3181.

[39] R. Gustinanda, L. M. Irham, W. Supadmi, and R. El Khair, “Profil Penggunaan CHOP dan RCHOP pada Pasien Limfoma Non-Hodgkin di RSUP Dr. Sardjito,” Jurnal Insan Farmasi Indonesia, vol. 8, no. 1, pp. 164–178, May 2025, doi: 10.36387/jifi.v8i1.2529.

[40] D. S. Setianingsih and D. N. C. Hanifa, “Cost Effectiveness Analysis (CEA) of Antihypertensives Use in Inpatient Hemodialysis Patients at Abdoel Wahab Sjahranie Hospital Samarinda,” Media Farmasi: Jurnal Ilmu Farmasi, vol. 22, no. 1, pp. 43–50, Apr. 2025, doi: 10.12928/mf.v22i1.30730.

[41] M. F. Fatkhiya, D. A. Perwitasari, and S. A. Febriana, “Analisis Biaya Sakit Perspektif Masyarakat pada Penderita DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) di RSUP Dr. Sardjito Yogyakarta,” Media Farmasi: Jurnal Ilmu Farmasi, vol. 17, no. 1, p. 49, Jan. 2021, doi: 10.12928/mf.v17i1.15928.

[42] F. Aminuddin, M. S. Bahari, N. A. Zainuddin, A. N. Mohd Hanafiah, and N. Z. A. Mohd Hassan, “The Direct and Indirect Costs of Cancer among the Lower-Income Group: Estimates from a Pilot and Feasibility Study,” Asian Pacific Journal of Cancer Prevention, vol. 24, no. 2, pp. 489–496, Feb. 2023, doi: 10.31557/APJCP.2023.24.2.489.

[43] C. E. Prastyo and A. Gani, “Medical cost inflation and its drivers in Indonesian employer-sponsored health insurance for retiree families,” Narra J, vol. 5, no. 2, p. e2528, May 2025, doi: 10.52225/narra.v5i2.2528.

[44] Muh. D. Kurniawan, E. Abdissalam, M. W. Ariawan, A. Rahem, Y. Yulistiani, and A. Wigatiningtyas, “Cost Disparities Between Hospital Expenditures and Reimbursement Schemes in Indonesia: A Study on Chemotherapy for Breast Cancer,” Asian Pacific Journal of Cancer Prevention, vol. 27, no. 3, pp. 999–1005, Mar. 2026, doi: 10.31557/APJCP.2026.27.3.999.

[45] I. Gąska et al., “Direct and Indirect Costs of Cancer in Adult Population of Poland in the Period 2021–2023,” Cancers (Basel)., vol. 17, no. 23, p. 3725, Nov. 2025, doi: 10.3390/cancers17233725.

[46] P. O. Mattila, Z.-U.-D. Babar, and F. Suleman, “Assessing the prices and affordability of oncology medicines for three common cancers within the private sector of South Africa,” BMC Health Serv. Res., vol. 21, no. 1, p. 661, Dec. 2021, doi: 10.1186/s12913-021-06627-6.

[47] A. Faggiano et al., “Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper,” Crit. Rev. Oncol. Hematol., vol. 180, p. 103826, Dec. 2022, doi: 10.1016/j.critrevonc.2022.103826.

[48] M. Yoo et al., “Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective,” JNCI: Journal of the National Cancer Institute, vol. 115, no. 11, pp. 1374–1382, Nov. 2023, doi: 10.1093/jnci/djad135.